We report a patient with extensive chronic-GVHD (c-GVHD) after BMT in whom pneumomediastinum and subcutaneous emphysema developed as the first sign of EBV post transplantation lymphoproliferative disease (PTLD) after long-lasting low loads of plasma EBV-DNA positivity.
event, loads spontaneously decreased to 100-300 copies/ml, and at the time of the event, the plasma viral load was 265 copies/ml.
Despite the low copy number, we suspected EBV-PTLD, for which the boy was treated with one course of rituximab (375 mg/m 2 once a week for 4 weeks). Seven days after the first dose, mediastinal masses resolved and pneumomediastinum spontaneously healed, although subcutaneous emphysema was still present (Figure 2 , black arrow). The viral load became normal after two doses of rituximab. Unfortunately, the patient died because of ongoing GVHD 6 months after BMT.
Pulmonary complications after BMT can be of infectious or non-infectious origin. They account for significant morbidity and mortality in these patients. 1 In the late phase after BMT, the impaired immune system and prolonged use of immunosuppressive therapy in patients with c-GVHD predisposes them to infections. [1] [2] [3] Post transplantation lymphoproliferative disease is one of the complications of BMT. The majority of patients presents with fever, lymphadenopathy, tonsilar enlargement and hepatosplenomegaly. Pulmonary involvement is generally part of the fulminant presentation of PTLD. It is associated with a high mortality. The relation between the intensity of immunosuppression and the risk of PTLD is 
clearly demonstrated. Patients on aggressive immunosuppression regimens are more at risk. 4 A number of groups have shown that EBV viremia is predictive of PTLD after T-cell-depleted SCT or after a reduced intensity-conditioning regimen. [5] [6] [7] It was also shown that an EBV-DNA threshold value of 10 5 copies/ ml is highly predictive of the diagnosis of PTLD. 8 Others have studied whether pre-emptive therapy with rituximab in high-risk BMT patients who develop EBV viremia prevents PTLD. Although no large, randomized studies have been performed in BMT settings, the existing data strongly support prevention of PTLD with rituximab, especially in the high-risk groups. 9 Patients with a plasma EBV DNA load 41000 copies/ml at two consecutive time points were considered to be at high risk to proceed to EBV-PTLD. Our patient never showed 41000 copies/ml on two repetitive occasions.
We presented a rare case of EBV-PTLD with fever, pneumomediastinum and subcutaneous emphysema. These were the first presenting symptoms in a pediatric patient with extensive c-GVHD, who had sustained low loads of plasma EBV-DNA. This case clearly demonstrates that in patients with prolonged highly immunosuppressive therapy, one should be aware of the risk of developing PTLD despite relatively low, although prolonged, positive loads of EBV-DNA in the plasma. This suggests that prolonged detectable loads may be a risk factor for the development of PTLD in these high-risk patients as well. As such, this might have implications for the current pre-emptive regimens. 
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